Liquidia (NASDAQ:LQDA) Insider Sells $149,377.60 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 5,245 shares of Liquidia stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $149,377.60. Following the completion of the transaction, the insider directly owned 115,241 shares in the company, valued at $3,282,063.68. This represents a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Up 2.5%

Shares of NASDAQ:LQDA opened at $34.78 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. Liquidia Corporation has a 1 year low of $21.94 and a 1 year high of $93.61. The stock has a market capitalization of $3.11 billion, a P/E ratio of 24.77 and a beta of 0.61. The stock has a 50-day simple moving average of $61.21 and a 200-day simple moving average of $61.73.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period last year, the company posted ($0.49) EPS. Equities analysts forecast that Liquidia Corporation will post 2.05 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on LQDA shares. Piper Sandler set a $129.00 price objective on shares of Liquidia in a research note on Friday, July 24th. HC Wainwright increased their price objective on shares of Liquidia from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank Of Canada set a $65.00 target price on shares of Liquidia in a research note on Thursday. Bank of America raised their target price on shares of Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Finally, Jefferies Financial Group upgraded shares of Liquidia to a “strong-buy” rating in a report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $72.85.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
• Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
• Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
• Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
• Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
• Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently modified their holdings of the stock. WINTON GROUP Ltd acquired a new stake in shares of Liquidia in the second quarter valued at about $335,000. Arizona State Retirement System raised its holdings in shares of Liquidia by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after buying an additional 900 shares during the period. Nykredit A S purchased a new stake in shares of Liquidia during the 2nd quarter valued at about $177,000. Corient Private Wealth LP purchased a new stake in shares of Liquidia during the 2nd quarter valued at about $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Liquidia during the 2nd quarter worth approximately $1,236,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).